Paired tumor/germline testing is far from standard practice in cancer care, but some experts in the field are advocating that when patients have their tumors genomically profiled to determine precision medicine options, that is an opportunity to also evaluate them for...
In 2019, the field of personalized medicine continued to grow with the market launch of more than two dozen drugs targeting novel genomic alterations and numerous genetic tests to determine whether patients are at risk for serious diseases like cancer, and whether...
Investigators at Ambry Genetics, the Mayo Clinic in Rochester, the University of Utah, and the University of California at Irvine have tapped into Ambry’s large collection of multigene panel test results to clarify hereditary cancer associations in high-risk...
Ellen T. Matloff, My Gene Counsel President and CEO, was featured in Nature last week discussing how misinterpreted results of genetic testing for cancer risk can result in unnecessary surgery. This story follow’s Angelina Jolie Pitt’s disclosure that she...
